India in dialogue with Moderna, other biotech firms over progress in COVID vaccine development: Sources


PTI, Nov 17, 2020, 11:57 AM IST

New Delhi: India is in dialogue with the US-based biotech giant Moderna over the progress in the clinical trials of its coronavirus vaccine candidate, which the firm said has shown 94.5 percent efficacy, official sources said on Monday.

Moderna on Monday said the independent National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, found the vaccine to have an efficacy of 94.5 percent.

“We are in dialogue not only with Moderna, but also with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila over the progress of the clinical trials of each of the vaccine candidates and where their vaccines stand in terms safety, immunogenicity and efficacy, and regulatory approvals,” a source said.

According to the New Drugs and Cosmetics Rules 2019, any new drug or vaccine which has been tested and got regulatory approval outside India, will have to undergo bridging phase 2 and 3 clinical studies for its secure regulatory approval here.

“As per law, the CDSCO, under the New Drugs and Cosmetics Rule 2019, can omit, relax or abbreviate the regulatory requirement or conditions of submitting pharmaceutical and clinical data of a vaccine candidate in Indian population in case of any emergency or pandemic like situation,” the source said.

Cambridge, Massachusetts-based Moderna”s announcement comes just a week after Pfizer and Biontech said their COVID-19 vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible,” said Stéphane Bancel, Chief Executive Officer of Moderna.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” he said.

Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (FDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data (with a median duration of at least 2 months).

Moderna also plans to submit applications for authorisations to global regulatory agencies.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Grenade attack on security personnel in Srinagar

‘Election king’ again files papers for poll

Union minister V K Singh calls NYT ‘Supari Media’ over its report on Pegasus

SBI suspends circular on recruitment of pregnant women

Rejected by New Zealand, reporter turns to Taliban for help

Hassan: Unable to repay Rs 1 lakh loan, couple murders friend at lodge

K’taka relaxes Covid restrictions: No night curfew, Schools in Bengaluru to reopen from Jan 31


Related Articles More

EXPLAINER: What’s known about “stealth” version of omicron?

Odisha made COVID-19 rapid antigen test kit gets ICMR approval

Risk persists even though Covid cases starting to plateau in parts of India: WHO

COVID: CM to hold expert committee meeting on lifting restrictions

Omicron dominates Covid third wave in Karnataka, minister clarifies deleting previous tweet

MUST WATCH

Elephant shot dead near Hunsur

Mangaluru: Youth loses life while trying to save drowning girlfriend

Newly Married womens deadbody fount in forest area

Mother of late police jawan builds memorial in his Honour

BSF seizes 47kg of heroin from Gurdaspur


Latest Additions

Manipur gets freight train connectivity; PM says it will enhance state’s commerce

Grenade attack on security personnel in Srinagar

BJP govt chased away criminals & mafias who flourished during SP regime in Uttar Pradesh: Shah

Rajasthan: Illicit liquor worth Rs 32 lakh seized, 2 held

‘Election king’ again files papers for poll

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.